| Nov 19 |
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Nov 16 |
Vaxart Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 14 |
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...
|
| Nov 13 |
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 13 |
Earnings Snapshot: Vaxart beats Q3 estimates; records R&D expenses of $15.1M
|
| Nov 13 |
Vaxart GAAP EPS of -$0.06 beats by $0.04, revenue of $4.93M beats by $3.43M
|
| Nov 13 |
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 12 |
Vaxart Q3 2024 Earnings Preview
|
